Integrins comprise a large family of cell surface receptors with critical roles in cancer cell proliferation, invasion and metastatic potential. Experiments carried out during the last funding cycle have uncovered a novel pathway of prostate cancer progression mediated by the av?6 integrin. We have found that av?6 is not expressed in human and mouse normal prostate but becomes significantly upregulated in preneoplastic lesions, prostatic adenocarcinoma (AdCa) and bone metastasis. Mechanistically, av?6 expression results in upregulation of androgen receptor (AR) activity via a JNK-mediated pathway. Our findings show, for the first time, that integrins modulate AR activity. In this pathway, we have identified survivin, a bifunctional regulator of cell division and inhibitor of apoptosis, as one of the critical downstream effector molecule which becomes upregulated in cells expressing av?6. Our in vivo data demonstrate that expression of av?6 results in enhanced tumor growth and metastatic dissemination as compared to a different av integrin, av?3. Expression of av?6 also causes tumor-mediated osteolysis, a crucial step in prostate cancer metastasis. Since av?3 has been shown to promote bone gain in prostate cancer metastatic lesions, we hypothesize that the extent of bone-lesion formation is controlled by the relative expression levels of av?6 and av?3. Finally, we show that these integrins'expression is regulated by two different transcription factors activated by TGF?: av?6 is induced via Smad3 activation, whereas av?3 expression is mediated by Runx2. We have formulated a unifying hypothesis that av?6 integrin functions as an integrator of multiple signaling pathways to promote early and late phases of prostate cancer progression. This hypothesis will be tested in the present renewal application by the following aims.
In Aim 1, the molecular mechanisms by which av?6 activates AR will be investigated.
In Aim 2, we will investigate in vivo the role of av?6 in prostate cancer progression in a mouse model of prostate cancer;for this purpose, we will use the prostate specific Pten-null mouse model which develops PIN, cancer and metastasis.
In Aim 3, to credential av integrins as molecular targets in prostate cancer bone lesion therapies, we will dissect the pathways by which av?6 and av?3 contribute to bone disease in vivo. Our long-term objective is to take advantage of this newly generated knowledge to develop novel molecular antagonists of prostate cancer progression.

Public Health Relevance

Studies carried out during the last cycle have uncovered a key role of the av?6 integrin in early and late stages of prostate cancer progression. We will dissect in the present application the pathways by which av?6 enhance tumorigenesis and metastatic bone disease. In parallel, we plan to perform an in vivo study to investigate whether an antibody to av?6 inhibits tumor progression in a mouse model of prostate cancer, Ptenpc-/-. This preclinical study in Ptenpc-/- mice, if successful, will pave the way for a clinical study which may help selecting patients with PTEN mutations {which represent approximately 50% of prostate cancer patients in the US} as the target patient population for av?6 inhibitors. The pathways described in the present application are relevant to the human disease since prostate cancer accounts for a significant cancer burden in USA, where in 2008 it was projected to result in over 28,000 deaths and more than 180,000 new cases. Large gaps still exist in our understanding of disease progression, and this has hampered the development of more effective drugs. New therapeutic approaches in advanced prostate cancer are urgently needed, and harnessing the frequent molecular defects in prostate tumors, such as Pten deficiency, may provide innovative therapeutic opportunities. By inhibiting av?6 - dependent signaling pathways, we will identify critical new approaches suitable for therapeutic intervention and pave the way for personalized therapies of prostate cancer. We will also gain insights in the mechanisms that promote bone metastasis, which is very frequent in prostate cancer patients and which results in severe bone pain, hypercalcemia, nerve compression and pathological fractures. Current treatments, chemotherapies, radiation and bisphosphonates all ameliorate components of the disease, but are not completely effective. Our long-term goal is to take advantage of our mechanistic studies to help develop novel molecular strategies for inhibition of prostate cancer progression in humans.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA089720-09
Application #
8462210
Study Section
Tumor Progression and Metastasis Study Section (TPM)
Program Officer
Woodhouse, Elizabeth
Project Start
2001-03-01
Project End
2015-04-30
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
9
Fiscal Year
2013
Total Cost
$256,012
Indirect Cost
$87,295
Name
Thomas Jefferson University
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
053284659
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Dutta, Anindita; Li, Jing; Lu, Huimin et al. (2014) Integrin ?v?6 promotes an osteolytic program in cancer cells by upregulating MMP2. Cancer Res 74:1598-608
Lisanti, Sofia; Tavecchio, Michele; Chae, Young Chan et al. (2014) Deletion of the mitochondrial chaperone TRAP-1 uncovers global reprogramming of metabolic networks. Cell Rep 8:671-7
Sayeed, Aejaz; Fedele, Carmine; Trerotola, Marco et al. (2013) IGF-IR promotes prostate cancer growth by stabilizing ?5?1 integrin protein levels. PLoS One 8:e76513
Trerotola, Marco; Jernigan, Danielle L; Liu, Qin et al. (2013) Trop-2 promotes prostate cancer metastasis by modulating ýý(1) integrin functions. Cancer Res 73:3155-67
Goel, Hira Lal; Sayeed, Aejaz; Breen, Michael et al. (2013) ýý1 integrins mediate resistance to ionizing radiation in vivo by inhibiting c-Jun amino terminal kinase 1. J Cell Physiol 228:1601-9
Saxena, Parmita; Trerotola, Marco; Wang, Tao et al. (2012) PSA regulates androgen receptor expression in prostate cancer cells. Prostate 72:769-76
Akech, J; Wixted, J J; Bedard, K et al. (2010) Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene 29:811-21
Mehrotra, Swarna; Languino, Lucia R; Raskett, Christopher M et al. (2010) IAP regulation of metastasis. Cancer Cell 17:53-64
Leav, Irwin; Plescia, Janet; Goel, Hira Lal et al. (2010) Cytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancer. Am J Pathol 176:393-401
Altieri, Dario C; Languino, Lucia R; Lian, Jane B et al. (2009) Prostate cancer regulatory networks. J Cell Biochem 107:845-52

Showing the most recent 10 out of 25 publications